Bispecific NKG2D-CD3 and NKG2D-CD16 Fusion Proteins as Novel Treatment Option in Advanced Soft Tissue Sarcomas.

Front Immunol · 2021 · PMC8079770 · PMID 33936075

Europe PMC DOI

hedged sentence

0.1500

closest p · 3.0× alpha

0.1500

boldest claim

The sentences

did not reach statistical significancep =0.15not close (p > 0.1)

Although NK cells of STS patients showed slightly decreased CD69 expression after treatment with NKG2D-CD16 compared to healthy donors ( Figure 5F ), this trend did not reach statistical significance ( p =0.15).

also in 111,027 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.